Publications To Date


    Filter Publications

    PAGE 3 OF 11 | DISPLAYING 31 - 45 OF 161 RESULTS

    Ignatiadis M. et. al., 2018 Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy., 10.1093/jnci/djy076., JNCI, May 18, 2018

    Biton J. et. al., 2018 TP53, STK11 and EGFR Mutations Predict Tumor Immune Profile and the Response to anti-PD-1 in Lung Adenocarcinoma., 10.1158/1078-0432.CCR-18-0163, Clin. Can. Res., May 15, 2018

    Zhang A.W. et. al., 2018 Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer., 10.1016/j.cell.2018.03.073., Cell, May 07, 2018

    Liu Z. et. al., 2018 Novel effector phenotype of Tim-3+ regulatory T cells leads to enhanced suppressive function in head and neck cancer patients., 10.1158/1078-0432.CCR-17-1350, Clin. Can. Res,, Apr 30, 2018

    Li Y. et. al., 2018 Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054, 10.1186/s40425-018-0329-7, J. Immunother, Cancer, Apr 30, 2018

    Vari F. et. al., 2018 Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL, 10.1182/blood-2017-07-796342, Blood, Apr 19, 2018

    Kim H. et. al., 2018 Development of a Validated Interferon Score Using NanoString Technology., 10.1089/jir.2017.0127., J. Interferon Cytokine Res., Apr 01, 2018

    Mu L. et. al., 2018 The IDH1 Mutation-Induced Oncometabolite, 2-Hydroxyglutarate, May Affect DNA Methylation and Expression of PD-L1 in Gliomas, 10.3389/fnmol.2018.00082, Front. Mol. Neurosci., Mar 28, 2018

    Bagaria S.P. et. al., 2018 Association Between Programmed Death-Ligand 1 Expression and the Vascular Endothelial Growth Factor Pathway in Angiosarcoma, 10.3389/fonc.2018.00071, Front. Oncol., Mar 22, 2018

    Zamarin D. et. al., 2018 PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy, 10.1172/JCI98047 , JCI, Mar 05, 2018

    Cooks T. et. al., Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246, 10.1038/s41467-018-03224-w, Nat. Commun., Feb 22, 2018

    Vari F. et. al., Immune evasion via PD-1/PD-L1 on NK-cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL., 10.1182/blood-2017-07-796342, Blood, Feb 15, 2018

    Sampath S. et. al., Combined modality radiation therapy promotes tolerogenic myeloid cell populations and STAT3-related gene expression in head and neck cancer patients, 10.18632/oncotarget.24397 , Oncotarget, Feb 02, 2018

    Revino L. et. al., Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation., 10.1172/JCI92812., JCI, Feb 01, 2018

    Ricca J.M. et. al., Pre-existing immunity to oncolytic virus potentiates its immunotherapeutic efficacy., 10.1016/j.ymthe.2018.01.019, Mol. Therapy, Jan 25, 2018